Rasdegafusp alfa

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Rasdegafusp alfa
Accession Number
DB15185
Description

Rasdegafusp alfa is under investigation in clinical trial NCT03206047 (Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer).

Type
Biotech
Groups
Investigational
Synonyms
Not Available
External IDs
  • CDX-1401

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
SU9AMV39DB
CAS number
1587257-96-2

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentCarcinoma of Unknown Primary Origin / Cutaneous Melanoma / Iris Melanoma / Medium/Large Size Posterior Uveal Melanoma / Mucosal Melanoma / NY-ESO-1 Positive Tumor Cells Present / Ocular Melanoma / Ocular Melanoma With Extraocular Extension / Small Size Posterior Uveal Melanoma / Stage IIB Cutaneous Melanoma AJCC v6 and v7 / Stage IIB Skin Melanoma / Stage IIB Uveal Melanoma / Stage IIC Cutaneous Melanoma AJCC v6 and v7 / Stage IIC Skin Melanoma / Stage III Cutaneous Melanoma AJCC v7 / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIA Skin Melanoma / Stage IIIA Uveal Melanoma / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIB Skin Melanoma / Stage IIIB Uveal Melanoma / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IIIC Skin Melanoma / Stage IIIC Uveal Melanoma / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Skin Melanoma / Stage IV Uveal Melanoma1
2WithdrawnTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1Active Not RecruitingTreatmentAcute Myeloid Leukemia (AML) / Blasts 30 Percent or Less of Bone Marrow Nucleated Cells / Chronic Myelomonocytic Leukemia / High Risk Myelodysplastic Syndrome / Myelodysplastic Syndrome / Refractory Anemia1
1CompletedTreatmentAcute Myeloid Leukemia (AML) / Alkylating Agent-Related Acute Myeloid Leukemia / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Refractory Anemia With Excess Blasts in Transformation1
1CompletedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligoastrocytoma / Anaplastic Oligodendroglioma (AO) / Estrogen Receptor Negative / Estrogen Receptor Positive / Glioblastomas / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Metastatic Renal Cell Cancer / Recurrent Adult Brain Neoplasm / Recurrent Bladder Carcinoma / Recurrent Breast Carcinoma / Recurrent Colorectal Carcinoma / Recurrent Esophageal Carcinoma / Recurrent Gastric Carcinoma / Recurrent Hepatocellular Carcinoma / Recurrent Lung Carcinoma / Recurrent Melanoma / Recurrent Ovarian Carcinoma / Recurrent Prostate Carcinoma / Recurrent Uterine Corpus Carcinoma / Renal Cell Carcinoma Recurrent / Resectable Hepatocellular Carcinoma / Sarcomas / Stage IA Breast Cancer / Stage IA Ovarian Cancer / Stage IA Uterine Corpus Cancer / Stage IB Breast Cancer / Stage IB Ovarian Cancer / Stage IB Uterine Corpus Cancer / Stage IC Ovarian Cancer / Stage II Uterine Corpus Cancer / Stage IIA Breast Cancer / Stage IIA Lung Carcinoma / Stage IIA Ovarian Cancer / Stage IIB Breast Cancer / Stage IIB Esophageal Cancer / Stage IIB Lung Carcinoma / Stage IIB Ovarian Cancer / Stage IIB Skin Melanoma / Stage IIC Ovarian Cancer / Stage IIC Skin Melanoma / Stage IIIA Breast Cancer / Stage IIIA Esophageal Cancer / Stage IIIA Lung Carcinoma / Stage IIIA Ovarian Cancer / Stage IIIA Skin Melanoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Breast Cancer / Stage IIIB Esophageal Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Skin Melanoma / Stage IIIB Uterine Corpus Cancer / Stage IIIC Breast Cancer / Stage IIIC Esophageal Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Skin Melanoma / Stage IIIC Uterine Corpus Cancer / Stage IV Bladder Urothelial Carcinoma / Stage IV Esophageal Cancer / Stage IV Ovarian Cancer / Stage IV Prostate Cancer / Stage IV Skin Melanoma / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
1, 2Active Not RecruitingTreatmentFallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Carcinoma1
1, 2CompletedTreatmentAdvanced Malignancies1
1, 2SuspendedTreatmentPlatinum-Resistant Fallopian Tube Carcinoma / Platinum-Resistant Ovarian Carcinoma / Platinum-Resistant Primary Peritoneal Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
1, 2TerminatedTreatmentUnresectable Stage III or Stage IV Melanoma1
1, 2WithdrawnTreatmentAdvanced Triple Negative Breast Cancer / Melanoma, Malignant / Mesothelioma / Non-Small Cell Lung Carcinoma (NSCLC) / Small Cell Lung Cancer (SCLC) / Urothelial Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 08:57 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates